Company intelligence / Profile preview

Innolife Co., Ltd.

Ownership: Private
Employees: ~250
Development stage: Phase 2

Overview

The company's lead product INL1 (Trientine Hydrochloride) for heart failure is in Phase 2 clinical trials. It was selected by the European Society of Cardiology as one of the 'Top 10 Breakthrough Studies of 2023' and works by delivering trace elements directly to damaged cardiac tissue.

Therapeutic areas: GastroenterologyCardiovascularNeurology
Modalities: Small molecule drugChemical drugs
Industry: Biotech

Drug pipeline

1 asset

INL1

Phase 2

Indications: Ischemic heart failure

Partnerships

Harvard UniversityNational Cardiovascular Center of the Chinese Academy of Medical Sciences

Beyond the preview

Go deeper on Innolife Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innolife Co., Ltd..

Explore the full profile